GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ibuzatrelvir   Click here for help

GtoPdb Ligand ID: 12897

Synonyms: compound 9 [PMID: 38687966] | Example 95 [US20220257563] | N-(Methoxycarbonyl)-3-methyl-L-valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-L-prolinamide | PF-07817883 | PF07817883
Compound class: Synthetic organic
Comment: PF-07817883 is an oral SARS-CoV-2 3CL (main) protease (Mpro) inhibitor. The compound and its use are claimed in patent US20220257563A1 [4]. We matched this chemical structure to the INN ibuzatrelvir from proposed INN list 129, and its formal disclosure in [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 12
Topological polar surface area 140.63
Molecular weight 489.49
XLogP 1.15
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H](C[C@@H]2CCNC2=O)C#N)C(F)(F)F)NC(=O)OC
Isomeric SMILES COC(=O)N[C@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H](C[C@@H]2CCNC2=O)C#N)C(F)(F)F)C(C)(C)C
InChI InChI=1S/C21H30F3N5O5/c1-20(2,3)15(28-19(33)34-4)18(32)29-10-12(21(22,23)24)8-14(29)17(31)27-13(9-25)7-11-5-6-26-16(11)30/h11-15H,5-8,10H2,1-4H3,(H,26,30)(H,27,31)(H,28,33)/t11-,12+,13-,14-,15+/m0/s1
InChI Key WGNWEPPRWQKSKI-AIEDFZFUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Bioactivity Comments
Ibuzatrelvir (ibuzatrelvir) is claimed to be devoid of off-target effects on drug metabolising cytochrome P450s [2]. For example, nirmatrelvir has to be co-adminstered with the CYP450 inhibitor ritonavir to get around its limited metabolic stability, and development of the COVID Moonshot lead DNDI-6510 was terminated as it suffered from clearance issues due to activation of CYP3A4.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CoV 3C-like (main) protease SARS-CoV-2 Inhibitor Inhibition 8.5 pKi - 4
pKi 8.5 (Ki 3x10-9 M) [4]